Inspire Investing LLC Decreases Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Inspire Investing LLC reduced its stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 18.9% during the second quarter, Holdings Channel.com reports. The institutional investor owned 12,972 shares of the company’s stock after selling 3,030 shares during the period. Inspire Investing LLC’s holdings in Dr. Reddy’s Laboratories were worth $988,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in RDY. Jane Street Group LLC boosted its stake in Dr. Reddy’s Laboratories by 2,197.8% in the first quarter. Jane Street Group LLC now owns 113,168 shares of the company’s stock valued at $8,301,000 after acquiring an additional 108,243 shares during the last quarter. BNP Paribas Financial Markets increased its position in Dr. Reddy’s Laboratories by 46.9% in the first quarter. BNP Paribas Financial Markets now owns 103,259 shares of the company’s stock worth $7,574,000 after buying an additional 32,958 shares during the last quarter. OLD Mission Capital LLC raised its stake in shares of Dr. Reddy’s Laboratories by 66.2% in the first quarter. OLD Mission Capital LLC now owns 47,537 shares of the company’s stock valued at $3,487,000 after buying an additional 18,930 shares during the period. O Shaughnessy Asset Management LLC lifted its position in shares of Dr. Reddy’s Laboratories by 11.3% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 62,177 shares of the company’s stock valued at $4,561,000 after buying an additional 6,322 shares during the last quarter. Finally, Artemis Investment Management LLP grew its stake in shares of Dr. Reddy’s Laboratories by 92.6% during the 2nd quarter. Artemis Investment Management LLP now owns 15,600 shares of the company’s stock worth $1,189,000 after acquiring an additional 7,500 shares during the period. Institutional investors own 14.02% of the company’s stock.

Dr. Reddy’s Laboratories Trading Up 0.2 %

NYSE:RDY opened at $78.52 on Friday. Dr. Reddy’s Laboratories Limited has a 1 year low of $63.72 and a 1 year high of $84.46. The stock’s fifty day moving average price is $81.16 and its two-hundred day moving average price is $75.72. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.55 and a quick ratio of 1.90. The company has a market cap of $13.10 billion, a P/E ratio of 19.48, a P/E/G ratio of 1.74 and a beta of 0.55.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its earnings results on Saturday, July 27th. The company reported $1.00 EPS for the quarter, missing the consensus estimate of $1.10 by ($0.10). Dr. Reddy’s Laboratories had a return on equity of 20.32% and a net margin of 19.28%. The company had revenue of $919.80 million during the quarter, compared to the consensus estimate of $861.68 million. As a group, analysts expect that Dr. Reddy’s Laboratories Limited will post 4.11 EPS for the current year.

Analyst Ratings Changes

Separately, Barclays upped their price objective on shares of Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the company an “overweight” rating in a report on Tuesday, July 30th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.